Tamas Hatfaludi, Mozhgan Sharokhyan Rezaee, Lise Vlerick, Tarik Sulejmanovic, Maarten De Gussem, Monita Vereecken, Koen De Gussem, Dieter Liebhart, Michael Hess
{"title":"单克隆肉鸡组织单胞菌活疫苗对火鸡的长期保护作用","authors":"Tamas Hatfaludi, Mozhgan Sharokhyan Rezaee, Lise Vlerick, Tarik Sulejmanovic, Maarten De Gussem, Monita Vereecken, Koen De Gussem, Dieter Liebhart, Michael Hess","doi":"10.1080/03079457.2025.2497814","DOIUrl":null,"url":null,"abstract":"<p><p>Histomonosis, caused by the protozoan parasite <i>Histomonas meleagridis</i>, is a major concern in turkey production due to the lack of licenced drugs and vaccines. Despite various studies on experimental vaccination, the duration of immunity of such a vaccine remains unclear. This study evaluated the long-term efficacy of an attenuated clonal monoxenic <i>H. meleagridis</i> culture in turkeys, focusing on its protective effects. Day-old turkeys were vaccinated orally using a frozen vaccine culture directly, without additional multiplication, and challenged 12 weeks later. The vaccine caused no adverse clinical signs, consistent with prior studies. Instead, vaccinated birds had an improved weight gain and higher body-weight at 42 days. Vaccine uptake was confirmed by the detection of histomonad DNA in faeces starting 14 days post-vaccination, coinciding with the first sampling time point, with 60-70% of birds testing positive by 49 days. Considering all sampling time-points before the challenge, every sampled vaccinated turkey secreted histomonads at least once. Following the challenge, analysed clinical scores showed a more than 20-fold reduction in disease severity in vaccinated birds compared to controls, and survival rates were remarkably higher in the vaccinated group (90%) than in non-vaccinated controls (16%). Overall, this study supports the long-term efficacy of the attenuated <i>H. meleagridis</i> vaccine, providing robust protection against histomonosis, reducing severity of clinical signs and a significant reduction of mortality, organ lesions as well as parasite burden. The vaccine's effectiveness, when administered at day-old, highlights its potential to prevent histomonosis, though challenges remain for widespread use in commercial turkey farming.<b>RESEARCH HIGHLIGHTS</b>Long-term efficacy of attenuated clonal monoxenic <i>H. meleagridis</i> vaccine was evaluated in turkeys.Long-term protection: Vaccine-protected turkeys from histomonosis for up to 84 days.Survival: 90% of vaccinated turkeys survived vs. 16% of non-vaccinated birds.Body-weights: Vaccinated birds weighed more, at 42 and 91-105 days of life.Lesions: Fewer liver/caecal lesions in vaccinated birds.</p>","PeriodicalId":8788,"journal":{"name":"Avian Pathology","volume":" ","pages":"633-644"},"PeriodicalIF":2.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term protection of turkeys with a live clonal monoxenic <i>Histomonas meleagridis</i> vaccine.\",\"authors\":\"Tamas Hatfaludi, Mozhgan Sharokhyan Rezaee, Lise Vlerick, Tarik Sulejmanovic, Maarten De Gussem, Monita Vereecken, Koen De Gussem, Dieter Liebhart, Michael Hess\",\"doi\":\"10.1080/03079457.2025.2497814\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Histomonosis, caused by the protozoan parasite <i>Histomonas meleagridis</i>, is a major concern in turkey production due to the lack of licenced drugs and vaccines. Despite various studies on experimental vaccination, the duration of immunity of such a vaccine remains unclear. This study evaluated the long-term efficacy of an attenuated clonal monoxenic <i>H. meleagridis</i> culture in turkeys, focusing on its protective effects. Day-old turkeys were vaccinated orally using a frozen vaccine culture directly, without additional multiplication, and challenged 12 weeks later. The vaccine caused no adverse clinical signs, consistent with prior studies. Instead, vaccinated birds had an improved weight gain and higher body-weight at 42 days. Vaccine uptake was confirmed by the detection of histomonad DNA in faeces starting 14 days post-vaccination, coinciding with the first sampling time point, with 60-70% of birds testing positive by 49 days. Considering all sampling time-points before the challenge, every sampled vaccinated turkey secreted histomonads at least once. Following the challenge, analysed clinical scores showed a more than 20-fold reduction in disease severity in vaccinated birds compared to controls, and survival rates were remarkably higher in the vaccinated group (90%) than in non-vaccinated controls (16%). Overall, this study supports the long-term efficacy of the attenuated <i>H. meleagridis</i> vaccine, providing robust protection against histomonosis, reducing severity of clinical signs and a significant reduction of mortality, organ lesions as well as parasite burden. The vaccine's effectiveness, when administered at day-old, highlights its potential to prevent histomonosis, though challenges remain for widespread use in commercial turkey farming.<b>RESEARCH HIGHLIGHTS</b>Long-term efficacy of attenuated clonal monoxenic <i>H. meleagridis</i> vaccine was evaluated in turkeys.Long-term protection: Vaccine-protected turkeys from histomonosis for up to 84 days.Survival: 90% of vaccinated turkeys survived vs. 16% of non-vaccinated birds.Body-weights: Vaccinated birds weighed more, at 42 and 91-105 days of life.Lesions: Fewer liver/caecal lesions in vaccinated birds.</p>\",\"PeriodicalId\":8788,\"journal\":{\"name\":\"Avian Pathology\",\"volume\":\" \",\"pages\":\"633-644\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Avian Pathology\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://doi.org/10.1080/03079457.2025.2497814\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avian Pathology","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1080/03079457.2025.2497814","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
Long-term protection of turkeys with a live clonal monoxenic Histomonas meleagridis vaccine.
Histomonosis, caused by the protozoan parasite Histomonas meleagridis, is a major concern in turkey production due to the lack of licenced drugs and vaccines. Despite various studies on experimental vaccination, the duration of immunity of such a vaccine remains unclear. This study evaluated the long-term efficacy of an attenuated clonal monoxenic H. meleagridis culture in turkeys, focusing on its protective effects. Day-old turkeys were vaccinated orally using a frozen vaccine culture directly, without additional multiplication, and challenged 12 weeks later. The vaccine caused no adverse clinical signs, consistent with prior studies. Instead, vaccinated birds had an improved weight gain and higher body-weight at 42 days. Vaccine uptake was confirmed by the detection of histomonad DNA in faeces starting 14 days post-vaccination, coinciding with the first sampling time point, with 60-70% of birds testing positive by 49 days. Considering all sampling time-points before the challenge, every sampled vaccinated turkey secreted histomonads at least once. Following the challenge, analysed clinical scores showed a more than 20-fold reduction in disease severity in vaccinated birds compared to controls, and survival rates were remarkably higher in the vaccinated group (90%) than in non-vaccinated controls (16%). Overall, this study supports the long-term efficacy of the attenuated H. meleagridis vaccine, providing robust protection against histomonosis, reducing severity of clinical signs and a significant reduction of mortality, organ lesions as well as parasite burden. The vaccine's effectiveness, when administered at day-old, highlights its potential to prevent histomonosis, though challenges remain for widespread use in commercial turkey farming.RESEARCH HIGHLIGHTSLong-term efficacy of attenuated clonal monoxenic H. meleagridis vaccine was evaluated in turkeys.Long-term protection: Vaccine-protected turkeys from histomonosis for up to 84 days.Survival: 90% of vaccinated turkeys survived vs. 16% of non-vaccinated birds.Body-weights: Vaccinated birds weighed more, at 42 and 91-105 days of life.Lesions: Fewer liver/caecal lesions in vaccinated birds.
期刊介绍:
Avian Pathology is the official journal of the World Veterinary Poultry Association and, since its first publication in 1972, has been a leading international journal for poultry disease scientists. It publishes material relevant to the entire field of infectious and non-infectious diseases of poultry and other birds. Accepted manuscripts will contribute novel data of interest to an international readership and will add significantly to knowledge and understanding of diseases, old or new. Subject areas include pathology, diagnosis, detection and characterisation of pathogens, infections of possible zoonotic importance, epidemiology, innate and immune responses, vaccines, gene sequences, genetics in relation to disease and physiological and biochemical changes in response to disease. First and subsequent reports of well-recognized diseases within a country are not acceptable unless they also include substantial new information about the disease or pathogen. Manuscripts on wild or pet birds should describe disease or pathogens in a significant number of birds, recognizing/suggesting serious potential impact on that species or that the disease or pathogen is of demonstrable relevance to poultry. Manuscripts on food-borne microorganisms acquired during or after processing, and those that catalogue the occurrence or properties of microorganisms, are unlikely to be considered for publication in the absence of data linking them to avian disease.